Blood-based tumour profiling provides less-invasive option for treatment-resistant prostate cancer

29/06/17

The Journal of the National Cancer Institute today published a landmark multi-institutional study describing the first comprehensive comparison of blood-based tumour biopsy versus metastatic tissue biopsy for lethal prostate cancer.

Led by PC-TRiADD PIs Wyatt, Chi and Gleave, this study showed that a blood-based test can identify all the important driver mutations that are detected in a tissue biopsy. This paves the way for blood-based tumour profiling to replace the need for the metastatic tissue biopsy in prostate cancer patients with treatment-resistant disease.

The work was funded by a Stand Up to Cancer Prostate Cancer Foundation Prostate Dream Team Translational Cancer Research Grant, with additional support provided by Prostate Cancer Canada through the Movember Rising Star in Prostate Cancer research program (AW), the Emil Aaltonen Foundation (MA), and a Terry Fox New Frontiers Program Project.

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer 
Alexander W. Wyatt, Matti Annala, Rahul Aggarwal, Kevin Beja, Felix Feng, Jack Youngren, Adam Foye, Paul Lloyd, Matti Nykter, Tomasz M. Beer, Joshi J. Alumkal, George V. Thomas, Robert E. Reiter, Matthew B. Rettig, Christopher P. Evans, Allen C. Gao, Kim N. Chi, Eric J. Small, Martin E. Gleave

 

News

Jul 26 2017

Dr. Zoubeidi awarded PCC-Movember Translation Acceleration Grant

July 26, 2017 - TORONTO, ON - Continuing their longstanding tradition of partnering to fund high quality Canadian prostate cancer research, Prostate Cancer Canada (PCC) and The Movember Foundation today announced two new projects with very real potential to make a tangible difference in the lives of men living with aggressive forms of prostate cancer.

Read more